[밸류업 점검] 셀트리온, CAGR 30% 실현 핵심은 美 약가 정책

Celltrion's ambitious 30% CAGR target hinges on its ability to navigate volatile US healthcare policies under the Trump administration. While aggressive drug price reductions pose a risk to biosimilar margins, they may simultaneously drive demand for cost-effective options and subcutaneous formulations like Zymfentra to improve fiscal health.